Roofe Lindsay R, Resha Donald J, Abramo Thomas J, Arnold Donald H
From the Department of Pediatric Emergency Medicine, Children's Hospital at Vanderbilt, 2200 Children's Way, Nashville, TN.
Pediatr Emerg Care. 2014 Jan;30(1):8-10. doi: 10.1097/PEC.0000000000000060.
The single-breath counting (SBC) method for assessment of asthma exacerbation severity has been evaluated in adults during exacerbations and in pediatric patients during routine settings. Single-breath counting has not been evaluated in children during exacerbations. We sought to assess criterion validity and responsiveness of SBC with percent-predicted FEV1 (%FEV1) and the Pediatric Respiratory Assessment Measure (PRAM), a validated acute asthma severity score.
We prospectively enrolled subjects aged 7 to 17 years with acute asthma exacerbations. Single-breath counting, %FEV1, and PRAM were obtained before treatment and 2 hours after initiating therapy. Multivariable linear regression models were used to examine associations of pretreatment SBC with %FEV1 and PRAM (criterion validity) and 2-hour change of these measures (responsiveness). With a 2-sided α of 0.05, SBC SD of 8.5, and 90% power to detect an adjusted R of greater than 0.36 for SBC with each outcome measure, a minimum sample of 20 participants was necessary.
From June to November 2011, 51 participants were enrolled, with median (interquartile range) age of 8.46 years (6.92-11.4 years); male sex, n = 40 (78%); and African American race, n = 33 (64%). Before treatment, 42 (92%) were able to successfully perform SBC, and 24 (51%) %FEV1. Median pretreatment SBC obtained was 16 (10-24); %FEV1, 50 (26-71); and PRAM, 5 (1-5).
Single-breath counting demonstrates modest criterion validity for predicting the pretreatment PRAM score and a trend for predicting %FEV1. Single-breath counting does not appear to be responsive to change of these measures in response to treatment and has limited validity as a measure of acute asthma severity.
单呼吸计数(SBC)法用于评估哮喘急性加重严重程度,已在成人急性加重期以及儿科患者日常情况下进行了评估。但单呼吸计数法尚未在儿童急性加重期进行评估。我们试图评估SBC与预测FEV1百分比(%FEV1)以及儿科呼吸评估量表(PRAM,一种经过验证的急性哮喘严重程度评分)的标准效度和反应性。
我们前瞻性纳入了7至17岁的急性哮喘加重患者。在治疗前和开始治疗2小时后获取单呼吸计数、%FEV1和PRAM。使用多变量线性回归模型来检验治疗前SBC与%FEV1和PRAM的相关性(标准效度)以及这些指标2小时的变化情况(反应性)。双侧α为0.05,SBC标准差为8.5,且有90%的把握度检测SBC与每个结局指标的校正R大于0.36,因此至少需要20名参与者的样本量。
2011年6月至11月,纳入了51名参与者,年龄中位数(四分位间距)为8.46岁(6.92 - 11.4岁);男性40名(78%);非裔美国人33名(64%)。治疗前,42名(92%)能够成功完成单呼吸计数,24名(51%)能够完成%FEV1测定。治疗前获得的SBC中位数为16(10 - 24);%FEV1为50(26 - 71);PRAM为5(1 - 5)。
单呼吸计数在预测治疗前PRAM评分方面显示出适度的标准效度,在预测%FEV1方面有一定趋势。单呼吸计数似乎对这些指标因治疗而产生的变化无反应,作为急性哮喘严重程度的一种测量方法,其效度有限。